# Gates Foundation

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/gates-foundation
Canonical HTML page: https://getbiobrief.com/entity/gates-foundation

## Timeline

- **2026-03-25**: Q1 Guidance — Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.
- **2026-01-15**: Albumin Commercialization — Dyadic and ProLiant Health launch recombinant albumin for global sales.
- **2025-12-31**: FY 2025 Close — Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.
- **2025-11-01**: Papzimius Launch — Precigen initiates commercial shipments of Papzimius for adult RRP.

## Recent coverage (1 stories)

### Commercial Inflection: Dyadic and Precigen Pivot to Product-Driven Revenue
2026-03-26 00:19:59 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.
Full story: https://getbiobrief.com/story/dyadic-precigen-q4-2025-commercial-pivot

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.